News

In the News
More
Q&A with Pulmocide CEO Garth Rapeport – Why Pulmocide is developing targeted lung therapy.
7 August 2019
Q&A with Pulmocide CEO Garth Rapeport – Why Pulmocide is developing targeted lung therapy. Read More
How to spot the hidden gem investment funds
29 June 2019
How to spot the hidden gem investment funds Read More
CardioFocus lands $55M in funding for product launches
28 May 2019
CardioFocus lands $55M in funding for product launches Read More
UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
20 May 2019
UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S. Read More
Press Releases
More
Bicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Bicycle®-based Immuno-oncology Therapies
25 February 2020
Bicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Bicycle®-based Immuno-oncology Therapies Read More
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
19 February 2020
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock Read More
Endotronix Announces Enrollment of the First Patients in the PROACTIVE-HF Pivotal Trial
18 February 2020
Endotronix Announces Enrollment of the First Patients in the PROACTIVE-HF Pivotal Trial Read More
AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and plato™ Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program
10 February 2020
AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and plato™ Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program Read More
Press Contacts
Michael-Jon Romano
Sommerfield Communications
T: (212) 255-8386
Events
More

View all events